Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma
REHOVOT, Israel and WASHINGTON and TEL AVIV, Israel, May 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) and Biolojic Design Ltd. (“Biolojic”), a biotechnology company using computational biology and artificial intelligence to design next generation, multifunctional antibodies known as multibodies, announced today that Teva initiated IND-enabling studies with BD9, a dual-specific multibody targeting both TSLP (Thymic stromal lymphopoietin) and IL-13. Teva has an exclusive license to develop BD9 for the treatment of TH2-driven inflammatory diseases such as atopic dermatitis and asthma.
Why Investors Should Watch Teva Despite Regional Risks
Despite the lack of cautious enthusiasm from retail investors in Teva, it continues to beat consensus estimates by wide margins and has once again raised its 2025 financial guidance. I highlight Austedo, Uzedy, the launch of biosimilars, and the more than successful development of duvakitug for the treatment of IBD in collaboration with Sanofi as key growth drivers. Moody's and Fitch also recently raised the Israeli pharmaceutical giant's credit ratings thanks to the continued strengthening of its balance sheet.
Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt
TEL AVIV, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today that it successfully upsized its offering and priced approximately $2,300,000,000 (equivalent) of its senior notes (the “Notes”). The principal amount of the offering was increased from the previously announced offering size of $2,000,000,000 (equivalent). Teva expects to use the net proceeds from the offerings (i) to fund the announced tender offers (collectively, the “Tender Offer”) to purchase, for cash, its 3.150% Senior Notes due 2026, 4.750% Sustainability-Linked Senior Notes due 2027, 3.750% Sustainability-Linked Senior Notes due 2027, 7.875% Sustainability-Linked Senior Notes due 2029, 7.375% Sustainability-Linked Senior Notes due 2029 and 8.125% Sustainability-Linked Senior Notes due 2031 (as it may be amended prior to expiration thereof), (ii) to pay fees and expenses in connection therewith and (iii) to the extent of any remaining proceeds, the repayment of outstanding debt upon maturity, tender offer or earlier redemption. Net proceeds may be temporarily invested pending application for their stated purpose.
Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy
TEL AVIV, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals (NYSE and TASE: TEVA) today announced that Fitch Ratings Agency (“Fitch”) has raised the Company's corporate credit rating to BB+, with a stable outlook; from BB. Fitch's report cites Teva's progress in reducing debt and improving flexibility, expects continuous revenue growth from AUSTEDO and AJOVY, as well as Teva's biosimilar pipeline.
Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031
TEL AVIV, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today that it has commenced tender offers (the “Offers”) to purchase for cash for a combined aggregate purchase price (exclusive of accrued and unpaid interest) of up to $2,000,000,000 (equivalent) (the “Total Maximum Amount”) of the following series of notes issued by finance subsidiaries of Teva and guaranteed by Teva:
Teva Announces Launch of $2,000,000,000 (Equivalent) Offering of Senior Notes
TEL AVIV, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today its intention to issue $2,000,000,000 (equivalent) of senior notes through its special purpose finance subsidiaries. Teva Pharmaceutical Finance Netherlands II B.V. (“Teva Finance II”) intends to offer EUR-denominated Senior Notes (the “Euro Notes”) and Teva Pharmaceutical Finance Netherlands III B.V. (“Teva Finance III”) and Teva Pharmaceutical Finance Netherlands IV B.V. (“Teva Finance IV” and, together with Teva Finance II and Teva Finance III, the “Issuers”) intend to offer USD-denominated Senior Notes (the “USD Notes” and, together with the Euro Notes, the “Notes”).
Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy
TEL AVIV, Israel, May 15, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals (NYSE and TASE: TEVA) today announced that Moody's Investor Services (“Moody's”) has raised the company's corporate credit rating to Ba1, outlook stable; from Ba2, outlook positive. Moody's report cites the Company's strengths which include significant global scale, ongoing growth in the company's branded franchises, stabilization of the company's generics business, focus on debt reduction and resolution of various legal liabilities Click Here
Teva's Transformation: Why This 'Forgotten Pharma' Could Deliver 30% Upside
Teva's betting big on biosimilars and specialty drugs, with AUSTEDO and UZEDY leading the charge. Management's $700 million cost-cutting plan is on track, aiming for a 30% operating margin by 2027. Recent FDA wins, like SELARSDI, show Teva's pushing into high-margin markets.
TEVA Beats on Q1 Earnings, Expects $700M Cost Savings by 2027, Stock Up
TEVA shares rise despite mixed first-quarter results. Teva lowers the higher end of its 2025 sales guidance while increasing the lower end of its EPS range.
Teva Pharma climbs as earnings impress
Shares in Teva Pharmaceutical Industries (NASDAQ:TEVA) rose 5% after publishing first-quarter earnings, where the Israeli company said US tariffs are expected to have an "immaterial impact". The Tel Aviv-based drugs maker reported revenue of $3.9 billion for the quarter, a 5% increase in local currency terms as key growth products continued to perform well, with operating income swinging to $519 million from a loss of $218 million a year ago.
Teva Pharmaceutical Industries Limited (TEVA) Q1 2025 Earnings Call Transcript
Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Q1 2025 Earnings Call May 7, 2025 8:00 AM ET Company Participants Christopher Stevo - SVP, IR Richard Francis - President & CEO Eric A. Hughes - EVP, Global R&D and Chief Medical Officer Eli Kalif - EVP & CFO Conference Call Participants David Amsellem - Piper Sandler Jason Gerberry - Bank of America Umer Raffat - Evercore ISI Ashwani Verma - UBS Investment Bank Christopher Schott - J.P.
Teva Pharmaceutical Industries (TEVA) Reports Q1 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Teva Pharmaceutical Industries (TEVA) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
